Medibio (ASX: MEB) (OTC: MDBIF) CEO Interview with David Kaysen. Mr. Kaysen recently came on board as the new CEO, in this interview he discusses Medibio's mental health monitoring technologies, ongoing progress towards full-scale commercializing, and his background in running small-cap med-tech companies. Kaysen sees 2019 as a "very important year for Medibio" with commercialization rollout, capital raising and FDA regulatory approvals.
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires June 15, 2019.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2